Harvard Licenses Technology to Obatala Sciences to Advance Discovery in Obesity, Diabetes, and Cancer
Development by New Orleans biotech company to enable studies of human fat tissue in vitro ...
Stay updated with breaking news from Biologically Inspired. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Development by New Orleans biotech company to enable studies of human fat tissue in vitro ...
Obatala Sciences, Harvard partner on human fat tissue study New Orleans-based biotechnology firm Obatala Sciences has been granted an exclusive license from Harvard University to commercialize innovations that enable the study of human fat tissue in vitro. The licensed Harvard technology, an adipose-on-a-chip, provides a method of obtaining adult-size fat tissue cells for study in vitro and enables the testing of weight loss and cancer-targeting therapeutics without the need for testing in animals, a news release said. It provides a more accurate and dynamic model of human tissue in its dise...
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
Share this article Share this article HOUSTON, May 25, 2021 /PRNewswire/ -- AuraVax Therapeutics, Inc. (Auravax), a biotech company developing novel intranasal therapeutics and vaccines to help patients defeat debilitating respiratory diseases, including COVID-19, today announced the formation of its inaugural Scientific Advisory Board (SAB), consisting of leading experts in the fields of biology, vaccines and intranasal drug delivery. The SAB will guide and advise the company in its ongoing development of proprietary therapeutics and vaccines for respiratory diseases. The SAB is chaired by ...
Published May 6, 2021 Permission granted by Eric Kelsic / Dyno Therapeutics Dyno Therapeutics, a Harvard University spinout working to improve gene therapy, is expanding with $100 million in new funding from tech investor Andreessen Horowitz and several other venture firms. Since officially launching a year ago, Dyno has struck deals with Novartis, Roche and Sarepta Therapeutics to aid their efforts to develop more efficient delivery of gene therapy. But even after doubling in size to 50 employees, the company hasn't been able to keep up...